In the current study inhibition of ubiquitin–proteasomal pathway by bortezomib in CML cells leads to induction of apoptosis via caspase-8 activation followed by truncation of Bid that resulted in a conformational change in the proapoptotic protein, Bax. This evidence concerns the gene CASP8 and chronic myelogenous leukemia, BCR-ABL1 positive.